SEC Comment Letter for Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282) (SYRE) — Feb 4, 2019
Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282)
Date: Feb. 4, 2019 · CIK: 0001636282 · Accession: 0000000000-19-000882
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228967
Letter
February 4, 2019 Anthony G. Quinn, M.B Ch.B, Ph.D. Chief Executive Officer Aeglea BioTherapeutics, Inc. 901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin, TX 78746 Re:Aeglea BioTherapeutics, Inc. Registration Statement on Form S-3 Filed December 21, 2018 File No. 333-228967 Dear Dr. Quinn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Robert A. Freedman, Esq. - Fenwick & West LLP
Show Raw Text
February 4, 2019
Anthony G. Quinn, M.B Ch.B, Ph.D.
Chief Executive Officer
Aeglea BioTherapeutics, Inc.
901 S. MoPac Expressway
Barton Oaks Plaza One
Suite 250
Austin, TX 78746
Re:Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed December 21, 2018
File No. 333-228967
Dear Dr. Quinn:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Robert A. Freedman, Esq. - Fenwick & West LLP